Brainsway (NASDAQ:BWAY) Given “Buy” Rating at HC Wainwright

Brainsway (NASDAQ:BWAY)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $19.00 price target on the stock. HC Wainwright‘s price objective suggests a potential upside of 58.60% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. LADENBURG THALM/SH SH lifted their target price on Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Zacks Research lowered shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Sunday, August 2nd. BTIG Research reissued a “buy” rating and issued a $20.00 price target on shares of Brainsway in a research note on Thursday, September 10th. Finally, New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.20.

Brainsway Price Performance

Shares of NASDAQ BWAY opened at $11.98 on Monday. The stock has a market capitalization of $482.20 million, a price-to-earnings ratio of 27.34 and a beta of 1.29. The business has a 50-day moving average of $13.50 and a 200-day moving average of $14.61. Brainsway has a fifty-two week low of $7.14 and a fifty-two week high of $17.40.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. The business had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.54 million. On average, sell-side analysts expect that Brainsway will post 0.33 EPS for the current year.

Hedge Funds Weigh In On Brainsway

Institutional investors have recently bought and sold shares of the business. Masters Capital Management LLC boosted its stake in Brainsway by 65.0% in the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after acquiring an additional 650,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after acquiring an additional 241,560 shares during the period. Y.D. More Investments Ltd boosted its holdings in Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock valued at $3,615,000 after purchasing an additional 157,042 shares during the last quarter. HWG Holdings LP acquired a new stake in Brainsway during the third quarter worth about $3,340,000. Finally, Sei Investments Co. lifted its stake in shares of Brainsway by 262.5% in the 1st quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock valued at $3,009,000 after purchasing an additional 163,925 shares during the period. 30.11% of the stock is owned by hedge funds and other institutional investors.

About Brainsway

BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive treatments for brain disorders. Its primary technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is delivered through specialized treatment systems and helmet-like coils.

The company’s Deep TMS platform is used by healthcare providers in the treatment of major depressive disorder, obsessive-compulsive disorder and smoking addiction, subject to applicable regulatory clearances and local treatment guidelines.